Cancer News and Research

Latest Cancer News and Research

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.

11 Sep 2012

Exercise, good nutrition play a crucial role in maintaining health and fighting disease

A new study just published in the journal Applied Physiology, Nutrition, and Metabolism (APNM) reaffirms the crucial role exercise along with good nutrition play in maintaining health and fighting disease.

11 Sep 2012

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

A molecule that targets the cell's machinery for breaking down unneeded proteins can kill multiple myeloma cancer cells resistant to the frontline drug Velcade, researchers at Dana-Farber Cancer Institute have found.

11 Sep 2012

Researchers discover small DNA sequence that drives GATA2 protein

The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result.

11 Sep 2012

Flow cytometry renders PCR testing unnecessary for most AML patients

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.

11 Sep 2012

Two different genetic mutations cooperate to induce adrenal cancer

Two different genetic mutations cooperate to induce adrenal cancer, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center and University of Sao Paulo in Brazil.

11 Sep 2012

HIF-1 activity directly responsible for spread of breast cancer to lymph vessels

The invasion of cancer cells into the lymph vessels that connect the breast to surrounding lymph nodes is the first step leading to the metastasis, or spread, of cancer throughout the body. Metastasis is the primary cause of breast cancer deaths. Surprisingly little is known about the control of this process and how it might be interrupted to prolong the lives of women with breast cancer.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Intermittent hormone therapy effective for prostate cancer patients

Intermittent androgen deprivation is as effective as continuous therapy for men with rising prostate-specific antigen levels after primary or salvage radiotherapy, say researchers who believe the break from treatment improves quality of life.

10 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

Florida Hospital Tampa and Dr. James E. Lefler are the first in the Tampa Bay area to adopt the new FDA approved device called the Trevo Pro Clot Retriever manufactured by Stryker. The Trevo Pro is the next generation in clot removal technology.

10 Sep 2012

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Scientists used genetic sequencing to discover new evidence that the first vaccine shown to prevent HIV infection in people also affected the viruses in those who did become infected. Viruses with two genetic "footprints" were associated with greater vaccine efficacy. The results were published today in the online edition of the journal Nature.

10 Sep 2012

Adult stem cell technology holds hope for erectile dysfunction treatment

After more than a decade of short-term cures to erectile dysfunction, most aimed at symptoms rather than the underlying issues of nerve damage, a new approach has emerged from adult stem cell technology developed by RNL Bio. Dr. Ji Youl Lee and the RNL Stem Cell Technology Institute (RNL SCTI) team, working at St. Mary's Hospital in Seoul, found in animal studies that adipose (fat) derived adult human stem cells, grown in culture, were very effective in treating cavernous nerve injury.

10 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

Automated system for mapping protein-DNA interactions

Since the sequencing of the human genome in 2001, all our genes - around 20,000 in total - have been identified. But much is still unknown - for instance where and when each is active. Next to each gene sits a short DNA segment, and the activity of this regulatory segment determines whether the gene will be turned on, where and how strongly.

10 Sep 2012

AB SCIEX launches Eksigent ekspert nanoLC 400 system

AB SCIEX, a global leader in life science analytical technologies, today announced the launch of the Eksigent ekspert nanoLC 400 system.

10 Sep 2012

Researchers identify many potential therapeutic targets for squamous cell lung cancers

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

10 Sep 2012

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

Less than half of community-based substance abuse treatment programs in the United States currently make HIV testing available on-site or through referral. A new study led by researchers at Weill Cornell Medical College shows the cost-effectiveness of integrating on-site rapid HIV testing into drug treatment programs.

10 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

Cancer News and Research

Latest Cancer News and Research

Cell Therapeutics launches Pixuvri in the European Union

Exercise, good nutrition play a crucial role in maintaining health and fighting disease

P5091 molecule triggers apoptosis in drug-resistant myeloma cells

Researchers discover small DNA sequence that drives GATA2 protein

Flow cytometry renders PCR testing unnecessary for most AML patients

Two different genetic mutations cooperate to induce adrenal cancer

HIF-1 activity directly responsible for spread of breast cancer to lymph vessels

Combining two drugs may offer new and potent punch against cancer and other diseases

Oxyphenbutazone can kill drug resistant TB

Intermittent hormone therapy effective for prostate cancer patients

'No malignancy risk' with biologic response modifiers

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Adult stem cell technology holds hope for erectile dysfunction treatment

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Automated system for mapping protein-DNA interactions

AB SCIEX launches Eksigent ekspert nanoLC 400 system

Researchers identify many potential therapeutic targets for squamous cell lung cancers

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in